{"id":63043,"date":"2026-04-13T20:55:03","date_gmt":"2026-04-13T12:55:03","guid":{"rendered":"https:\/\/flcube.com\/?p=63043"},"modified":"2026-04-13T20:55:05","modified_gmt":"2026-04-13T12:55:05","slug":"astrazenecas-imjudo-gains-nmpa-approval-for-first-line-nsclc-in-china-backed-by-poseidon-data","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63043","title":{"rendered":"AstraZeneca&#8217;s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data"},"content":{"rendered":"\n<p><strong>AstraZeneca plc<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NYSE\">NYSE: AZN<\/a>) has secured marketing approval from China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>Imjudo (tremelimumab)<\/strong>. The CTLA-4 inhibitor is approved for use in combination with <strong>Imfinzi (durvalumab)<\/strong> and platinum-based chemotherapy as a first-line treatment for adults with metastatic <strong>non-small cell lung cancer (NSCLC)<\/strong> whose tumors are negative for EGFR sensitive mutations and ALK alterations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-approval-amp-clinical-basis\">Regulatory Approval &amp; Clinical Basis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regimen<\/strong><\/td><td>Imjudo (tremelimumab) + Imfinzi (durvalumab) + Platinum Chemotherapy<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>1L metastatic NSCLC (EGFR-\/ALK-)<\/td><\/tr><tr><td><strong>Basis for Approval<\/strong><\/td><td>Phase III <strong>POSEIDON<\/strong> clinical trial<\/td><\/tr><tr><td><strong>Dosing Schedule<\/strong><\/td><td>Tremelimumab: 5 cycles; Durvalumab + Chemo: 4 cycles<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-poseidon-trial-key-results\">POSEIDON Trial Key Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Combination Regimen<\/th><th>Chemotherapy Alone<\/th><th>Hazard Ratio (HR)<\/th><th>p-value<\/th><\/tr><\/thead><tbody><tr><td><strong>Overall Survival (OS)<\/strong><\/td><td>Median 14.0 months; 2-year rate ~33%<\/td><td>Median 11.7 months; 2-year rate 22%<\/td><td>HR 0.77 (95% CI: 0.65\u20130.92)<\/td><td>0.00304<\/td><\/tr><tr><td><strong>Progression-Free Survival (PFS)<\/strong><\/td><td>Significant improvement<\/td><td>\u2014<\/td><td>HR 0.72 (95% CI: 0.60\u20130.86)<\/td><td>0.00031<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>Consistent with known profiles of Imjudo and Imfinzi; no new safety signals identified<\/td><td><\/td><td><\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-mechanism-amp-strategic-context\">Drug Mechanism &amp; Strategic Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action:<\/strong> <strong>Tremelimumab<\/strong>, a first-generation anti-CTLA-4 monoclonal antibody (originally from Pfizer), blocks the CTLA-4 checkpoint on T-cells, thereby enhancing their activation and anti-tumor immune response.<\/li>\n\n\n\n<li><strong>Differentiated IO Approach:<\/strong> This approval establishes AstraZeneca\u2019s unique <strong>STRIDE regimen<\/strong> (Single Tremelimumab Regular Interval Durvalumab) in China, differentiating it from other PD-(L)1-based combinations by adding a short course of CTLA-4 inhibition for a potent, yet time-limited, immune boost.<\/li>\n\n\n\n<li><strong>Addressing High Unmet Need:<\/strong> The approval provides a new, more effective standard of care for the large population of Chinese NSCLC patients without actionable EGFR or ALK drivers, who have historically relied on chemotherapy alone.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact\">Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Edge:<\/strong> The significant <strong>23% reduction in risk of death<\/strong> and improved long-term survival rates position the Imjudo\/Imfinzi combo as a highly compelling option in the crowded first-line NSCLC market.<\/li>\n\n\n\n<li><strong>Franchise Expansion:<\/strong> This approval significantly broadens the commercial footprint of AstraZeneca\u2019s immuno-oncology franchise in China, leveraging the established presence of Imfinzi.<\/li>\n\n\n\n<li><strong>Global Validation:<\/strong> The NMPA\u2019s decision, based on the global POSEIDON data, reinforces the regimen\u2019s efficacy and safety, supporting its adoption as a new global standard of care.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief reports on a marketing approval from the NMPA. Commercial success is subject to pricing, reimbursement, and market acceptance. Prescribing information is based on the POSEIDON trial and is subject to change.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca plc (NYSE: AZN) has secured marketing approval from China\u2019s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63045,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[130,16,4621,15],"class_list":["post-63043","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-astrazeneca","tag-cancer","tag-nyse-azn","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca&#039;s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca plc (NYSE: AZN) has secured marketing approval from China\u2019s National Medical Products Administration (NMPA) for Imjudo (tremelimumab). The CTLA-4 inhibitor is approved for use in combination with Imfinzi (durvalumab) and platinum-based chemotherapy as a first-line treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are negative for EGFR sensitive mutations and ALK alterations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63043\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca&#039;s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca plc (NYSE: AZN) has secured marketing approval from China\u2019s National Medical Products Administration (NMPA) for Imjudo (tremelimumab). The CTLA-4 inhibitor is approved for use in combination with Imfinzi (durvalumab) and platinum-based chemotherapy as a first-line treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are negative for EGFR sensitive mutations and ALK alterations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63043\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-13T12:55:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-13T12:55:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1307.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63043#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63043\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca&#8217;s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data\",\"datePublished\":\"2026-04-13T12:55:03+00:00\",\"dateModified\":\"2026-04-13T12:55:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63043\"},\"wordCount\":384,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63043#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1307.webp\",\"keywords\":[\"AstraZeneca\",\"Cancer\",\"NYSE:\u202fAZN\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63043#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63043\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63043\",\"name\":\"AstraZeneca's Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63043#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63043#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1307.webp\",\"datePublished\":\"2026-04-13T12:55:03+00:00\",\"dateModified\":\"2026-04-13T12:55:05+00:00\",\"description\":\"AstraZeneca plc (NYSE: AZN) has secured marketing approval from China\u2019s National Medical Products Administration (NMPA) for Imjudo (tremelimumab). The CTLA-4 inhibitor is approved for use in combination with Imfinzi (durvalumab) and platinum-based chemotherapy as a first-line treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are negative for EGFR sensitive mutations and ALK alterations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63043#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63043\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63043#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1307.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1307.webp\",\"width\":1080,\"height\":608,\"caption\":\"AstraZeneca's Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63043#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca&#8217;s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca's Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca plc (NYSE: AZN) has secured marketing approval from China\u2019s National Medical Products Administration (NMPA) for Imjudo (tremelimumab). The CTLA-4 inhibitor is approved for use in combination with Imfinzi (durvalumab) and platinum-based chemotherapy as a first-line treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are negative for EGFR sensitive mutations and ALK alterations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63043","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca's Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data","og_description":"AstraZeneca plc (NYSE: AZN) has secured marketing approval from China\u2019s National Medical Products Administration (NMPA) for Imjudo (tremelimumab). The CTLA-4 inhibitor is approved for use in combination with Imfinzi (durvalumab) and platinum-based chemotherapy as a first-line treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are negative for EGFR sensitive mutations and ALK alterations.","og_url":"https:\/\/flcube.com\/?p=63043","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-13T12:55:03+00:00","article_modified_time":"2026-04-13T12:55:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1307.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63043#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63043"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca&#8217;s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data","datePublished":"2026-04-13T12:55:03+00:00","dateModified":"2026-04-13T12:55:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63043"},"wordCount":384,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63043#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1307.webp","keywords":["AstraZeneca","Cancer","NYSE:\u202fAZN","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63043#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63043","url":"https:\/\/flcube.com\/?p=63043","name":"AstraZeneca's Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63043#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63043#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1307.webp","datePublished":"2026-04-13T12:55:03+00:00","dateModified":"2026-04-13T12:55:05+00:00","description":"AstraZeneca plc (NYSE: AZN) has secured marketing approval from China\u2019s National Medical Products Administration (NMPA) for Imjudo (tremelimumab). The CTLA-4 inhibitor is approved for use in combination with Imfinzi (durvalumab) and platinum-based chemotherapy as a first-line treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are negative for EGFR sensitive mutations and ALK alterations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63043#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63043"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63043#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1307.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1307.webp","width":1080,"height":608,"caption":"AstraZeneca's Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63043#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca&#8217;s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1307.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63043","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63043"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63043\/revisions"}],"predecessor-version":[{"id":63046,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63043\/revisions\/63046"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63045"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63043"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63043"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63043"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}